Cargando…

Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study

SIMPLE SUMMARY: Fibroblast growth factor-23 (FGF-23) is used to monitor chronic kidney disease in humans. The value of FGF-23 in cats is largely unknown. The aim of this study was to compare three different FGF-23 diagnostic assays and to assess their correlation with renal function parameters in ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Lapsina, Sandra, Nagler, Nicole, Müller, Simon F., Holtdirk, Annette, Kottmann, Tanja, Müller, Elisabeth, von Luckner, Jennifer, Schäfer, Ingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251965/
https://www.ncbi.nlm.nih.gov/pubmed/37889764
http://dx.doi.org/10.3390/ani13111853
_version_ 1785056058031472640
author Lapsina, Sandra
Nagler, Nicole
Müller, Simon F.
Holtdirk, Annette
Kottmann, Tanja
Müller, Elisabeth
von Luckner, Jennifer
Schäfer, Ingo
author_facet Lapsina, Sandra
Nagler, Nicole
Müller, Simon F.
Holtdirk, Annette
Kottmann, Tanja
Müller, Elisabeth
von Luckner, Jennifer
Schäfer, Ingo
author_sort Lapsina, Sandra
collection PubMed
description SIMPLE SUMMARY: Fibroblast growth factor-23 (FGF-23) is used to monitor chronic kidney disease in humans. The value of FGF-23 in cats is largely unknown. The aim of this study was to compare three different FGF-23 diagnostic assays and to assess their correlation with renal function parameters in cats. Four groups were formed retrospectively on the basis of creatinine concentration classification according to the IRIS guidelines. Measurements were performed in 40 cats in total. The Kainos ELISA assay (FGF-23 ELISA Kit, Kainos Laboratories, Tokyo, Japan) showed the highest correlations for all study groups. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD. ABSTRACT: Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone used to monitor chronic kidney disease (CKD) in humans. The aim of this pilot study was to compare three diagnostic assays and to assess how the results correlate with parameters of renal dysfunction in cats. Four groups of 10 cats each were formed retrospectively according to creatinine, based on IRIS staging. FGF-23 was measured using two different ELISAs (MyBioSource and Kainos ELISA FGF-23 Kit) and an automated assay on the DiaSorin Liaison platform. Measurements were performed in 40 cats. Spearman’s rank correlation coefficient showed a strong correlation between the Kainos and DiaSorin assays (ρ = 0.742/p < 0.001) and a low correlation (ρ = 0.443/p = 0.005) between the Kainos and MyBioSource assays. The measurements with the Kainos assay strongly correlated with urea (ρ = 0.835/p < 0.001) and creatinine (ρ = 0.764/p < 0.001), and moderately correlated with SDMA (ρ = 0.580/p < 0.001) and phosphorus (ρ = 0.532/p < 0.001). The results of the MyBioSource and DiaSorin assays only showed a moderate correlation with urea (ρ = 0.624/0.572) and creatinine (ρ = 0.622/0.510) concentrations (p = 0.001 each). The Kainos assay showed the strongest correlation (ρ = 0.806) with the various creatinine concentrations according to the IRIS, followed by the MyBioSource (ρ = 0.663/p < 0.001) and DiaSorin assays (ρ = 0.580/p < 0.001). Overall, the Kainos assay demonstrated the best correlations with both biomarkers and various creatinine concentrations according to the IRIS. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD.
format Online
Article
Text
id pubmed-10251965
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102519652023-06-10 Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study Lapsina, Sandra Nagler, Nicole Müller, Simon F. Holtdirk, Annette Kottmann, Tanja Müller, Elisabeth von Luckner, Jennifer Schäfer, Ingo Animals (Basel) Article SIMPLE SUMMARY: Fibroblast growth factor-23 (FGF-23) is used to monitor chronic kidney disease in humans. The value of FGF-23 in cats is largely unknown. The aim of this study was to compare three different FGF-23 diagnostic assays and to assess their correlation with renal function parameters in cats. Four groups were formed retrospectively on the basis of creatinine concentration classification according to the IRIS guidelines. Measurements were performed in 40 cats in total. The Kainos ELISA assay (FGF-23 ELISA Kit, Kainos Laboratories, Tokyo, Japan) showed the highest correlations for all study groups. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD. ABSTRACT: Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone used to monitor chronic kidney disease (CKD) in humans. The aim of this pilot study was to compare three diagnostic assays and to assess how the results correlate with parameters of renal dysfunction in cats. Four groups of 10 cats each were formed retrospectively according to creatinine, based on IRIS staging. FGF-23 was measured using two different ELISAs (MyBioSource and Kainos ELISA FGF-23 Kit) and an automated assay on the DiaSorin Liaison platform. Measurements were performed in 40 cats. Spearman’s rank correlation coefficient showed a strong correlation between the Kainos and DiaSorin assays (ρ = 0.742/p < 0.001) and a low correlation (ρ = 0.443/p = 0.005) between the Kainos and MyBioSource assays. The measurements with the Kainos assay strongly correlated with urea (ρ = 0.835/p < 0.001) and creatinine (ρ = 0.764/p < 0.001), and moderately correlated with SDMA (ρ = 0.580/p < 0.001) and phosphorus (ρ = 0.532/p < 0.001). The results of the MyBioSource and DiaSorin assays only showed a moderate correlation with urea (ρ = 0.624/0.572) and creatinine (ρ = 0.622/0.510) concentrations (p = 0.001 each). The Kainos assay showed the strongest correlation (ρ = 0.806) with the various creatinine concentrations according to the IRIS, followed by the MyBioSource (ρ = 0.663/p < 0.001) and DiaSorin assays (ρ = 0.580/p < 0.001). Overall, the Kainos assay demonstrated the best correlations with both biomarkers and various creatinine concentrations according to the IRIS. Individual assay-based reference values should be established to make a reliable interpretation of FGF-23 levels possible to diagnose or monitor feline CKD. MDPI 2023-06-02 /pmc/articles/PMC10251965/ /pubmed/37889764 http://dx.doi.org/10.3390/ani13111853 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lapsina, Sandra
Nagler, Nicole
Müller, Simon F.
Holtdirk, Annette
Kottmann, Tanja
Müller, Elisabeth
von Luckner, Jennifer
Schäfer, Ingo
Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study
title Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study
title_full Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study
title_fullStr Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study
title_full_unstemmed Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study
title_short Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study
title_sort comparison of three different diagnostic assays for fibroblast growth factor-23 (fgf-23) measurements in cats: a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251965/
https://www.ncbi.nlm.nih.gov/pubmed/37889764
http://dx.doi.org/10.3390/ani13111853
work_keys_str_mv AT lapsinasandra comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy
AT naglernicole comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy
AT mullersimonf comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy
AT holtdirkannette comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy
AT kottmanntanja comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy
AT mullerelisabeth comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy
AT vonlucknerjennifer comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy
AT schaferingo comparisonofthreedifferentdiagnosticassaysforfibroblastgrowthfactor23fgf23measurementsincatsapilotstudy